Spryson

We are living through the most important moment in the history of brain health.

For the first time, we have treatments for Alzheimer's disease that actually work. Not treatments that manage symptoms — treatments that slow the disease itself. Lecanemab. Donanemab. Approved. Available. Real.

For Parkinson's disease, disease-modifying therapies are in Phase 3 trials right now. The science is arriving. The treatments are coming.

But here is the problem.

Every one of these treatments only works if you find the patient early enough. Before significant neurological damage has occurred. In the window when intervention can still make a difference.

And right now — today — there is no reliable, scalable, objective way to find those patients.

Neurology is the only major medical specialty that still runs almost entirely on subjective assessment. Questionnaires. Cognitive tests. Clinical observation. The same tools we had fifty years ago.

Every other organ system has a performance layer. Cardiology has the ECG. Endocrinology has HbA1c. Pulmonology has FEV₁. You measure at forty so that the measurement at fifty means something.

The brain has no equivalent. Until now.

What we are building at Spryson is that layer. The objective, measurable, trackable performance layer for the brain. The infrastructure that every clinician, every health system, every pharma company, and every person who wants to understand their brain health will eventually run on.

Neurological conditions are now the leading cause of illness and disability worldwide. Ahead of cardiovascular disease. Ahead of cancer. Three billion people. And the treatments to help them are arriving. The platform to find them in time — that is what we are building.

This is the opportunity.

I want to tell you what Spryson is not.

It is not a research project. It is not a prototype. It is not a hypothesis looking for funding to find out if it works.

Spryson is a cleared, revenue-generating, commercially deployed neurological intelligence platform. And I want to walk you through what that actually means.

We have five FDA clearances. Class II medical device clearances — the regulatory standard that took ten years and more than twenty million dollars to build. Those clearances cover the measurement of eye movements and balance system responses as neurological diagnostic tools. They cannot be rushed. They cannot be shortcut. A competitor starting today cannot replicate them in under a decade.

We have 350 customers. Clinicians and researchers across the United States and internationally who are using our platform today — in their practices, with their patients, generating real clinical data. Not beta users. Not pilot sites. Paying customers.

We are operationally self-sustaining. This raise is not survival capital. The business generates revenue. The platform works. We are raising to scale what already exists — not to build what doesn't.

We have thirty years of scientific validation behind us. Sixty peer-reviewed publications. Three thousand validating articles. Trusted by NASA, the US Army, Mayo Clinic, Johns Hopkins, and UPMC.

And we have the reference database. In 2021 we published the normative dataset for this technology — four hundred and sixty-six subjects, nine oculomotor and cognitive tests, FDA cleared for clinical use. In that paper we named its own limitation: the age range stopped at forty-five. We are now closing that gap. Pediatric through eighty-five and above, sampled to reflect the American population. Nobody else has this. Nobody can shortcut building it.

The technology risk is gone. The regulatory risk is substantially de-risked. The commercial model is proven.

And the advantage compounds. Every clearance widens what we can measure. Every install widens who we measure. Every assessment makes the platform better. A competitor would need our clearances, our installed base, and four years — before reaching the starting line.

What the $25 million does is pull a lever. A lever that took thirty years and fifty million dollars to build. The platform exists. We are ready.

Let me tell you about Flatiron Health.

Flatiron was an oncology data company. They built a platform that collected real-world cancer patient data from clinical practices across the United States. Two million records. Longitudinal. Multi-site. Deeply structured.

Roche acquired them for $1.9 billion.

Not because of the software. Not because of the technology. Because of the data.

The neurological equivalent of that dataset does not exist. Anywhere in the world.

No one has a large-scale, deeply phenotyped, longitudinally tracked neurological database. Not pharma. Not health systems. Not Google. Not anyone.

Spryson is building it. And I want to be precise about how, because there are two datasets here, not one, and they do different jobs.

The first is regulatory evidence. Small, rigorous, adjudicated studies designed to win FDA clearance — two major indications a year, ten over five years. A few hundred confirmed cases per indication, each one measured against an accepted reference standard. That is what makes the platform billable, prescribable, and reimbursable. It is deliberately small, deliberately expensive, and it is fully budgeted.

The second is the real-world cohort. Two hundred thousand people, measured in the course of ordinary care.

And here is what makes it different from anything that exists. Every patient contributes objective eye movement and balance measurement — eight hundred variables. The validated clinical scores their doctor already collects. And brain-health blood and hormone panels. Objective neurological function, measured against biochemistry and against outcome, in the same person, over years. No clinical trial has ever produced that.

So who pays for it?

Pharma. And not for the raw data — for recruitment. CNS trials fail on enrollment more often than they fail on efficacy. Sponsors screen dozens of patients to randomise one, and they pay for every screen. We hold a consented population, phenotyped by objective measurement rather than by diagnosis code — including patients whose brain function is already changing but who carry no diagnosis at all and appear in no claims database anywhere.

That is what pharma is actually buying. And it is a business we expect to be worth fifteen to forty million a year in recurring revenue by our Series B — none of which is in our projections.

The first dataset makes us cleared. The second makes us impossible to catch. And the advantage compounds — every clearance widens what we can measure, every install widens who we measure, and every assessment makes the platform better. A competitor would need our clearances, our installed base, and four years before reaching the starting line.

Three billion people. One platform. The brain health infrastructure of the 21st century.

That is what we are building.

I want to tell you about eight people.

A 47-year-old woman with persistent brain fog who has seen three doctors and been told everything is normal — but knows something is wrong. A Spryson assessment gives her a number. An objective signal. A starting point.

A 52-year-old man whose mother had Alzheimer's. He's frightened. His GP has no tool to assess his risk today. Spryson establishes his neurological baseline — so that when something changes, we will see it before he does.

A GP with twelve patients a week reporting neurological symptoms and no objective tool to assess any of them. A 25-minute assessment and a structured clinical report. She can act now — not in six months.

A neurologist whose waiting room is full. Every patient arrives without a baseline. Spryson gives him the profile before the consultation begins. He can focus on interpretation and intervention, not information gathering.

A pharma researcher trying to recruit early-stage Parkinson's patients for a Phase 3 trial. Traditional recruitment takes years. Spryson's database identifies matching patients from existing clinical data. The trial that changes Parkinson's treatment gets to market faster.

A 58-year-old executive spending thirty thousand dollars a year on his longevity program — cardiovascular, metabolic, genetic, hormonal — with one organ never objectively measured. His brain. Until now.

A rehabilitation patient six weeks into vestibular therapy, with no way to know if it's working. Spryson remeasures against his baseline. The improvement is visible. The protocol is adjusted. The work is proven.

And a hospital network that wants to build a neurological prevention program across twenty sites — without a specialist neurologist at every location. Spryson deploys in weeks. Every assessment feeds the same database. The program improves with every patient it sees.

Eight people. Eight moments. One platform.

That is the width of this opportunity. And we are only at the beginning.